Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Agios Pharmaceuticals
(NASDAQ:AGIO)
Intraday
$29.12
0
[0.00%]
After-Hours
$29.12
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$29.12
0
[0.00%]
At close: Mar 27
$29.12
0
[0.00%]
PreMarket: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Agios Pharmaceuticals Stock (NASDAQ:AGIO)
Agios Pharmaceuticals Stock (NASDAQ: AGIO)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, February 16, 2024
RBC Capital Maintains Outperform on Agios Pharmaceuticals, Lowers Price Target to $42
Benzinga Newsdesk
-
Feb 16, 2024, 11:58AM
Thursday, February 15, 2024
Agios Pharmaceuticals Q4 Sales $7.10M Miss $7.94M Estimate
Benzinga Newsdesk
-
Feb 15, 2024, 7:03AM
Earnings Scheduled For February 15, 2024
Benzinga Insights
-
Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
Earnings Preview: Agios Pharmaceuticals
Benzinga Insights
-
Feb 14, 2024, 12:01PM
Monday, January 08, 2024
Agios Pharmaceuticals Announced Strong Cash Position Expected To Support Completion Of Ongoing Programs And Disciplined Pipeline Expansion At Least Into 2026
Charles Gross
-
Jan 8, 2024, 7:21AM
Wednesday, January 03, 2024
Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?
Vandana Singh
-
Jan 3, 2024, 9:45AM
Market-Moving News for January 3rd
Benzinga Newsdesk
-
Jan 3, 2024, 8:36AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Jan 3, 2024, 8:05AM
Agios Pharmaceuticals shares are trading higher after the company announced its Phase 3 ENERGIZE study of Mitapivat met its primary and both key secondary endpoints.
Benzinga Newsdesk
-
Jan 3, 2024, 7:56AM
Agios Announces Phase 3 ENERGIZE Study Of Mitapivat Met Primary Endpoint And Both Key Secondary Endpoints In Adults With Non-Transfusion-Dependent Alpha- Or Beta-Thalassemia
Benzinga Newsdesk
-
Jan 3, 2024, 6:33AM
Sunday, December 10, 2023
Agios Presented Results Saturday From Phase 2 Portion Of RISE UP Pivotal Study In Sickle Cell Disease At ASH Meeting; Said Treatment With Mitapivat Demonstrated Statistically Significant Improvement In Hemoglobin Response Compared To Placebo
Charles Gross
-
Dec 10, 2023, 7:36AM
Monday, November 20, 2023
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
Benzinga Newsdesk
-
Nov 20, 2023, 7:04AM
Friday, November 03, 2023
Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $28
Benzinga Newsdesk
-
Nov 3, 2023, 10:18AM
Thursday, November 02, 2023
Agios Pharmaceuticals To Present Broad Set Of Clinical And Translational Data In Rare Blood Disorders At 65th ASH Annual Meeting and Exposition
Benzinga Newsdesk
-
Nov 2, 2023, 9:22AM
Agios Pharmaceuticals' Cash, Cash Equivalents And Marketable Securities Of $872.4M Is Expected To Provide Cash Runway At Least Into 2026
Benzinga Newsdesk
-
Nov 2, 2023, 7:10AM
Agios Pharmaceuticals Q3 EPS $(1.64) Beats $(1.70) Estimate, Sales $7.40M Miss $7.52M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 7:08AM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Tuesday, August 22, 2023
Agios Pharmaceuticals Insider Trades Send a Signal
Benzinga Insights
-
Aug 22, 2023, 11:03AM
Thursday, August 10, 2023
Principal Accounting Officer At This Health Care Company Sells $74K of Stock
Benzinga Insights
-
Aug 10, 2023, 11:04AM
Monday, August 07, 2023
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $32
Benzinga Newsdesk
-
Aug 7, 2023, 11:43AM
Thursday, August 03, 2023
Earnings Scheduled For August 3, 2023
Benzinga Insights
-
Aug 3, 2023, 6:59AM
Agios Pharmaceuticals Has Announced Exclusive Worldwide License Agreement For Alnylam Pharmaceuticals' Preclinical siRNA Targeting TMPRSS6 For Polycythemia Vera; Agios Will Pay An Upfront Of $17.5M And Up To $130M In Milestone Payments
Benzinga Newsdesk
-
Aug 3, 2023, 6:49AM
Agios Pharmaceuticals Q2 EPS $(1.51) Beats $(1.60) Estimate, Sales $6.71M Beat $6.67M Estimate
Benzinga Newsdesk
-
Aug 3, 2023, 6:36AM
Tuesday, June 27, 2023
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
Benzinga Insights
-
Jun 27, 2023, 1:00PM
RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $42
Benzinga Newsdesk
-
Jun 27, 2023, 7:43AM
Monday, June 26, 2023
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
Vandana Singh
-
Jun 26, 2023, 12:23PM
Agios Pharmaceuticals Says Phase 2 Portion Of The Global Rise Up Study Of Mitapivat In Sickle Cell Disease Met Its Primary Endpoint Of Hemoglobin Response For Patients In Both The 50mg And 100mg Twice Daily Mitapivat Arms
Benzinga Newsdesk
-
Jun 26, 2023, 6:31AM
Monday, May 15, 2023
Agios Pharmaceuticals's Return On Capital Employed Overview
Benzinga Insights
-
May 15, 2023, 10:47AM
Thursday, May 04, 2023
Agios Pharmaceuticals: Q1 Earnings Insights
Benzinga Insights
-
May 4, 2023, 7:37AM
Agios Pharmaceuticals Q1 EPS $(1.47) Beats $(1.70) Estimate, Sales $5.61M Beat $5.23M Estimate
Benzinga Newsdesk
-
May 4, 2023, 7:13AM
Earnings Scheduled For May 4, 2023
Benzinga Insights
-
May 4, 2023, 6:34AM
Friday, February 24, 2023
Agios Pharmaceuticals's Return On Capital Employed Insights
Benzinga Insights
-
Feb 24, 2023, 9:50AM
Thursday, February 23, 2023
Agios Reports Cash, Cash Equivalents And Marketable Securities As Of December 31, 2022 Of $1.1B
Benzinga Newsdesk
-
Feb 23, 2023, 7:22AM
Agios Pharmaceuticals FY EPS $(4.23) Beats $(6.56) Estimate, Sales $14.24M Beat $14.18M Estimate
Benzinga Newsdesk
-
Feb 23, 2023, 7:20AM
Earnings Scheduled For February 23, 2023
Benzinga Insights
-
Feb 23, 2023, 5:18AM
Friday, February 03, 2023
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Benzinga Insights
-
Feb 3, 2023, 10:00AM
Piper Sandler Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces Price Target of $41
Benzinga Newsdesk
-
Feb 3, 2023, 5:02AM
Thursday, December 01, 2022
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $33
Benzinga Newsdesk
-
Dec 1, 2022, 8:29AM
Thursday, November 17, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Benzinga Insights
-
Nov 17, 2022, 10:13AM
Agios Pharmaceuticals's Return On Capital Employed Overview
Benzinga Insights
-
Nov 17, 2022, 9:48AM
Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral, Raises Price Target to $32
Benzinga Newsdesk
-
Nov 17, 2022, 8:24AM
Friday, November 11, 2022
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
Vandana Singh
-
Nov 11, 2022, 11:03AM
Thursday, November 10, 2022
Agios Pharmaceuticals Announces PYRUKYND Approved In The EU For The Treatment Of Pyruvate Kinase Deficiency In Adult Patients
Benzinga Newsdesk
-
Nov 10, 2022, 4:30PM
Thursday, November 03, 2022
Agios Pharmaceuticals: Q3 Earnings Insights
Benzinga Insights
-
Nov 3, 2022, 7:43AM
Agios Pharmaceuticals Q3 EPS $(1.49) Beats $(1.76) Estimate, Sales $3.52M Miss $5.24M Estimate
Benzinga Newsdesk
-
Nov 3, 2022, 7:13AM
Earnings Scheduled For November 3, 2022
Benzinga Insights
-
Nov 3, 2022, 5:42AM
Thursday, October 27, 2022
Agios And Sagard Healthcare Partners Announce $131.8M Purchase Agreement For TIBSOVO Royalty
Benzinga Newsdesk
-
Oct 27, 2022, 4:44PM
Monday, September 19, 2022
Agios Named Cecilia Jones as CFO
Charles Gross
-
Sep 19, 2022, 7:07AM
Friday, September 16, 2022
Agios Receives Positive CHMP Opinion For PYRUKYND For Treatment Of Pyruvate Kinase (PK) Deficiency In Adult Patients
Bill Haddad
-
Sep 16, 2022, 6:43AM
Friday, September 02, 2022
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
Lisa Levin
-
Sep 2, 2022, 5:29AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch